Movement Alert｜Exelixis Falls 5.7% in Regular Trading, Post-Earnings Profit-Taking Drives Sell-Off

Market Focus08-07

On August 7, Exelixis fell 5.7% in regular trading, trading at $53.44/share, with turnover of $102 million. The decline came as investors chose to lock in profits following the company's latest quarterly earnings release.

Exelixis reported earnings on August 5 with an adjusted EPS of $0.82, modestly above the consensus estimate of $0.79. Heading into the report, the market had high expectations for continued volume growth in core product Cabometyx and advancement of the pipeline, particularly zanzalintinib which is under FDA review. Despite the earnings beat, funds opted for profit-taking given the stock's prior run-up.

For context, consensus had projected quarterly revenue of approximately $636 million, representing 10.71% year-over-year growth, with adjusted EPS growth of over 40%. Recent catalysts included positive Phase III data for Cabometyx in neuroendocrine tumors showing 74% risk reduction, and a clinical development collaboration with Merck on the Stellar-316 trial in colorectal cancer.

Exelixis is an oncology-focused biopharmaceutical company specializing in small molecule cancer therapies, with cabozantinib-based products CABOMETYX and COMETRIQ as its commercial backbone.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114681440?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114681440","market":"us","top_or_hot":-1,"title":"Movement Alert｜Exelixis Falls 5.7% in Regular Trading, Post-Earnings Profit-Taking Drives Sell-Off","media":"Market Focus","content":"<p><p>On August 7, Exelixis fell 5.7% in regular trading, trading at $53.44/share, with turnover of $102 million. The decline came as investors chose to lock in profits following the company's latest quarterly earnings release.</p><p>Exelixis reported earnings on August 5 with an adjusted EPS of $0.82, modestly above the consensus estimate of $0.79. Heading into the report, the market had high expectations for continued volume growth in core product Cabometyx and advancement of the pipeline, particularly zanzalintinib which is under FDA review. Despite the earnings beat, funds opted for profit-taking given the stock's prior run-up.</p><p>For context, consensus had projected quarterly revenue of approximately $636 million, representing 10.71% year-over-year growth, with adjusted EPS growth of over 40%. Recent catalysts included positive Phase III data for Cabometyx in neuroendocrine tumors showing 74% risk reduction, and a clinical development collaboration with Merck on the Stellar-316 trial in colorectal cancer.</p><p>Exelixis is an oncology-focused biopharmaceutical company specializing in small molecule cancer therapies, with cabozantinib-based products CABOMETYX and COMETRIQ as its commercial backbone.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Exelixis Falls 5.7% in Regular Trading, Post-Earnings Profit-Taking Drives Sell-Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Exelixis Falls 5.7% in Regular Trading, Post-Earnings Profit-Taking Drives Sell-Off\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Exelixis fell 5.7% in regular trading, trading at $53.44/share, with turnover of $102 million. The decline came as investors chose to lock in profits following the company's latest quarterly earnings release.</p><p>Exelixis reported earnings on August 5 with an adjusted EPS of $0.82, modestly above the consensus estimate of $0.79. Heading into the report, the market had high expectations for continued volume growth in core product Cabometyx and advancement of the pipeline, particularly zanzalintinib which is under FDA review. Despite the earnings beat, funds opted for profit-taking given the stock's prior run-up.</p><p>For context, consensus had projected quarterly revenue of approximately $636 million, representing 10.71% year-over-year growth, with adjusted EPS growth of over 40%. Recent catalysts included positive Phase III data for Cabometyx in neuroendocrine tumors showing 74% risk reduction, and a clinical development collaboration with Merck on the Stellar-316 trial in colorectal cancer.</p><p>Exelixis is an oncology-focused biopharmaceutical company specializing in small molecule cancer therapies, with cabozantinib-based products CABOMETYX and COMETRIQ as its commercial backbone.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"","article_id":"1114681440","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114681440","pubTimestamp":1786032939,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Exelixis fell 5.7% in regular trading, trading at $53.44/share, with turnover of $102 million. The decline came as investors chose to lock in profits following the company's latest...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯"},"translate_title":"走势警报|Exelixis 常规交易下跌 5.7%，财报后获利了结推动抛售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1},"content_text":"On August 7, Exelixis fell 5.7% in regular trading, trading at $53.44/share, with turnover of $102 million. The decline came as investors chose to lock in profits following the company's latest quarterly earnings release.Exelixis reported earnings on August 5 with an adjusted EPS of $0.82, modestly above the consensus estimate of $0.79. Heading into the report, the market had high expectations for continued volume growth in core product Cabometyx and advancement of the pipeline, particularly zanzalintinib which is under FDA review. Despite the earnings beat, funds opted for profit-taking given the stock's prior run-up.For context, consensus had projected quarterly revenue of approximately $636 million, representing 10.71% year-over-year growth, with adjusted EPS growth of over 40%. Recent catalysts included positive Phase III data for Cabometyx in neuroendocrine tumors showing 74% risk reduction, and a clinical development collaboration with Merck on the Stellar-316 trial in colorectal cancer.Exelixis is an oncology-focused biopharmaceutical company specializing in small molecule cancer therapies, with cabozantinib-based products CABOMETYX and COMETRIQ as its commercial backbone.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114681440","isCrawlerRequest":true}